RxDoctor Payments Data

Michelle Decker

Psychiatric/Mental Health · Warrington, PANPI 1942917984

Payments from drug & device makers

$2,712in general payments, 2019–2025

Across 118 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$727
  • AbbVie$283
  • Axsome Therapeutics, Inc.$236
  • Alkermes, Inc.$210
  • Lundbeck LLC$176
  • E.r. Squibb & Sons, L.L.C.$175
  • plus $905 from 14 others

What the payments were for

  • Food & beverage$2,66598%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,712 in reported general payments places this provider in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,803
Medicare patients
129
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$18,002
VraylarCariprazine Hcl13$17,990
Aripiprazole42$2,105
Duloxetine Hcl54$2,020
Sertraline Hcl174$1,876
Escitalopram Oxalate84$992
Vilazodone Hcl18$921
Bupropion Hcl SrBupropion Hcl38$762
Venlafaxine Hcl ErVenlafaxine Hcl18$660
Mirtazapine44$575
Clonazepam41$448
Quetiapine Fumarate53$390
Buspirone Hcl28$315
Olanzapine18$279
Bupropion XlBupropion Hcl12$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$154$18,00213 claims
AbbVieVraylar$283$17,99013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Warrington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →